References
- Schetz M, Lauwers PM, Ferdinande P. Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view. Intensive Care Med 1989;15:349-357.
- Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial 2009;22:141-145. https://doi.org/10.1111/j.1525-139X.2008.00545.x
- Van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996;7:145-150.
- Reeves JH, Cumming AR, Gallagher L, O’Brien JL, Santamaria JD. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999;27:2224-2228. https://doi.org/10.1097/00003246-199910000-00026
- Journois D, Safran D, Castelain MH, Chanu D, Drevillon C, Barrier G. Comparison of the antithrombotic effects of heparin, enoxaparin and prostacycline in continuous hemofiltration. Ann Fr Anesth Reanim 1990;9:331-337. https://doi.org/10.1016/S0750-7658(05)80244-8
- Van der Voort PH, Gerritsen RT, Kuiper MA, Egbers PH, Kingma WP, Boerma EC. Filter run time in CVVH: pre-versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif 2005;23:175-180.
- Kim HC, Han SY, Kim HK, Cho WY, Sung SA, Park SK, et al. A multi-center phase III clinical trial to assess the influence to bleeding and anticoagulant effect of Nafamostat Mesilate (Futhan) in hemodialysis patients with high bleeding-risk. Korean Renal Med 2004;6:920-926.
- Okada H, Suzuki H, Deguchi N, Saruta T. Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostate mesilate. Nephrol Dial Transplant 1992;7:980.
- Park II, Choi MJ, Yoon JW, Lee YK, Kim SG, Oh JE, et al. Saline versus nafamostat mesilate anticoagulation for continuous veno-venous hemofiltration (CVVH) in patients at high risk of bleeding: a prospective study. Korean J Nephrol 2009;28:205-210.
- Kinnunen EM, Juvonen T, Airaksinen KE, Heikkinen J, Kettunen U, Mariscalco G, et al. Clinical significance and determinants of the universal definition of perioperative bleeding classification in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2014;148:1640-1646. https://doi.org/10.1016/j.jtcvs.2014.07.040
- Fealy N, Aitken L, Toit Ed, Baldwin I. Continuous renal replacement therapy: current practice in Australian and New Zealand intensive care units. Crit Care Resusc 2015;17:83-91.
- Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail 2012;34:279-285. https://doi.org/10.3109/0886022X.2011.647293
- Lee SH, Kwon SK, Kim HY. Outcome and prognosis in patients receiving continuous renal replacement therapy. Kidney Res Clin Pract 2010;29:434-440.
- Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs 2016;39:16-21. https://doi.org/10.5301/ijao.5000465
- Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs 2013;36:208-216. https://doi.org/10.5301/ijao.5000191
- Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007;33:1563-1570. https://doi.org/10.1007/s00134-007-0754-4
- Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991;93:215-217.
- Lee YK, Lee HW, Choi KH, Kim BS. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One 2014;9:e108737. https://doi.org/10.1371/journal.pone.0108737
- Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine (Baltimore) 2015;94:e2392 https://doi.org/10.1097/MD.0000000000002392